The analysis of the correlation between FGL2 expression and IPS revealed that BLCA patients with high FGL2 expression exhibited higher IPS on anti-PD1 and anti-CTLA4 therapy. The gene discussed is FGL2; the disease is bladder transitional cell carcinoma.